From the Document: "Following the Food and Drug Administration's (FDA) emergency authorization of the Pfizer/BioNTech [hyperlink], Moderna [hyperlink], and Janssen Biotech/Johnson & Johnson [hyperlink] vaccines against COVID-19 [coronavirus disease 2019], millions of Americans [hyperlink] have received at least one dose of a COVID-19 vaccine regimen. Based on months-long clinical trials (including safety monitoring) of each vaccine candidate involving tens of thousands of participants, FDA did not [hyperlink] identify any [hyperlink] safety concerns for these vaccines that would preclude FDA emergency use authorization. As with most vaccines, however, a very small percentage of inoculated individuals experienced adverse reactions to a COVID-19 vaccine. Anecdotal reports [hyperlink] from early in the COVID-19 vaccination campaign include several cases of anaphylaxis--a severe and potentially life-threatening allergic reaction--following vaccination. [...] Federal law has two distinct vaccination compensation regimes that may compensate individuals harmed by adverse reactions. In general, the National Vaccine Injury Compensation Program [hyperlink] (VICP) may provide compensation for injuries or deaths associated with most vaccines [hyperlink] routinely administered in the United States (such as pediatric and seasonal influenza vaccines). During certain public health emergencies, the Countermeasures Injury Compensation Program [hyperlink] (CICP) may provide compensation for injuries and deaths resulting from the administration of 'covered countermeasures' under the Public Readiness and Emergency Preparedness Act [hyperlink] (PREP Act), which may include vaccines."
CRS Legal Sidebar, LSB10584
Congressional Research Service: https://crsreports.congress.gov/